Suppr超能文献

分化型人类甲状腺癌中的INT-2基因扩增

INT-2 gene amplification in differentiated human thyroid cancer.

作者信息

Schulte K M, Niederacher D, An H X, Staudt S, Simon D, Beckmann M W, Goretzki P E

机构信息

Department of General Surgery, Heinrich-Heine-University, Düsseldorf, Germany.

出版信息

Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4. doi: 10.1055/s-0029-1211713.

Abstract

Oncogene amplification is frequent in many epithelial tumors and often associated with advanced tumor progression. In different epithelial neoplasias it helps to provide prognostic information on individual patients. The present study was performed to evaluate the hitherto unknown prevalence of INT-2 gene amplification and its potential usefulness as prognostic marker in patients with human thyroid cancer. We used differential quantitative polymerase chain reaction and fluorescent DNA technique as a reliable method to detect low copy-number amplification of oncogenes from archival carcinoma specimens. Sequences from the int-2 gene and the single copy gamma-interferon gene were amplified simultaneously by PCR and quantified on a fluorescence activated sequencer. Native tumor tissue from 63 patients with differentiated thyroid cancer (43 papillary, 3 oncocytary, and 17 follicular) and from 12 goiters was analyzed by differential quantitative polymerase chain reaction. The study group contained many far advanced tumors. 40% of tumors were recurrent, 35% were staged T4 tumors and 70% presented with lymph node metastases. The prevalence of INT-2 amplification was 12% for follicular and 7% for papillary carcinomas. In goiter tissue no amplification was found. Amplification was only 2-4fold in positive cases. Low grade amplification is of no apparent importance in differentiated thyroid cancer.

摘要

癌基因扩增在许多上皮性肿瘤中很常见,且常与肿瘤的晚期进展相关。在不同的上皮性肿瘤中,它有助于为个体患者提供预后信息。本研究旨在评估INT-2基因扩增此前未知的患病率及其作为人类甲状腺癌患者预后标志物的潜在用途。我们使用差异定量聚合酶链反应和荧光DNA技术作为一种可靠的方法,从存档的癌组织标本中检测癌基因的低拷贝数扩增。通过PCR同时扩增int-2基因和单拷贝γ-干扰素基因的序列,并在荧光激活测序仪上进行定量。采用差异定量聚合酶链反应分析了63例分化型甲状腺癌患者(43例乳头状癌、3例嗜酸细胞癌和17例滤泡状癌)以及12例甲状腺肿患者的原发肿瘤组织。研究组包含许多进展期肿瘤。40%的肿瘤复发,35%为T4期肿瘤,70%有淋巴结转移。滤泡状癌和乳头状癌的INT-2扩增患病率分别为12%和7%。在甲状腺肿组织中未发现扩增。阳性病例中的扩增仅为2至4倍。低级别扩增在分化型甲状腺癌中似乎没有明显意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验